WO1997026862A3 - Verbesserte konzentrierte injektions- und infusionslösungen für die intravasale anwendung - Google Patents

Verbesserte konzentrierte injektions- und infusionslösungen für die intravasale anwendung Download PDF

Info

Publication number
WO1997026862A3
WO1997026862A3 PCT/DE1997/000170 DE9700170W WO9726862A3 WO 1997026862 A3 WO1997026862 A3 WO 1997026862A3 DE 9700170 W DE9700170 W DE 9700170W WO 9726862 A3 WO9726862 A3 WO 9726862A3
Authority
WO
WIPO (PCT)
Prior art keywords
infusion solutions
intravenous administration
concentrated injection
improved concentrated
injection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE1997/000170
Other languages
English (en)
French (fr)
Other versions
WO1997026862A2 (de
Inventor
Ulrich Speck
Gabriele Schuhmann-Giampieri
Peter Muschick
Werner Krause
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PL97328199A priority Critical patent/PL328199A1/xx
Priority to SK1013-98A priority patent/SK101398A3/sk
Priority to AT97914098T priority patent/ATE251893T1/de
Priority to BR9707081A priority patent/BR9707081A/pt
Priority to EP97914098A priority patent/EP0876140B1/de
Priority to DE59710863T priority patent/DE59710863D1/de
Priority to JP9526441A priority patent/JP2000505789A/ja
Priority to DK97914098T priority patent/DK0876140T3/da
Priority to AU21504/97A priority patent/AU2150497A/en
Application filed by Schering AG filed Critical Schering AG
Priority to CA002244209A priority patent/CA2244209C/en
Priority to IL12467697A priority patent/IL124676A0/xx
Publication of WO1997026862A2 publication Critical patent/WO1997026862A2/de
Publication of WO1997026862A3 publication Critical patent/WO1997026862A3/de
Priority to BG102644A priority patent/BG62913B1/bg
Priority to NO983438A priority patent/NO983438L/no
Anticipated expiration legal-status Critical
Priority to US09/504,108 priority patent/US6638913B1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0452—Solutions, e.g. for injection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Es werden Zusätze zu konzentrierten Injektions- und Infusionslösungen, die akute oder verzögerte Überempfindlichkeitsreaktionen vermeiden oder vermindern sowie Injektions- und Infusionslösungen, die diese Zusätze enthalten, beschrieben.
PCT/DE1997/000170 1996-01-25 1997-01-27 Verbesserte konzentrierte injektions- und infusionslösungen für die intravasale anwendung Ceased WO1997026862A2 (de)

Priority Applications (14)

Application Number Priority Date Filing Date Title
AU21504/97A AU2150497A (en) 1996-01-25 1997-01-27 Improved concentrated injection and infusion solutions for intravenous adminis tration
AT97914098T ATE251893T1 (de) 1996-01-25 1997-01-27 Verbesserte kontrastmittenlösungen für die intravasale anwendung
CA002244209A CA2244209C (en) 1996-01-25 1997-01-27 Improved concentrated injection and infusion solutions for intravenous administration
EP97914098A EP0876140B1 (de) 1996-01-25 1997-01-27 Verbesserte kontrastmittenlösungen für die intravasale anwendung
DE59710863T DE59710863D1 (de) 1996-01-25 1997-01-27 Verbesserte kontrastmittenlösungen für die intravasale anwendung
JP9526441A JP2000505789A (ja) 1996-01-25 1997-01-27 注射及び輸液用として血管内に使用する改良された濃縮溶液
DK97914098T DK0876140T3 (da) 1996-01-25 1997-01-27 Forbedrede kontrastmiddelopløsninger til intravasal anvendelse
PL97328199A PL328199A1 (en) 1996-01-25 1997-01-27 Improved concentrated intravascular injection and infusion solutions
BR9707081A BR9707081A (pt) 1996-01-25 1997-01-27 Soluções de injeção e infusão concentradas aperfeiçoadas para aplicação intravasal
SK1013-98A SK101398A3 (en) 1996-01-25 1997-01-27 Improved concentrated injection and infusion solutions for intravenous administration
IL12467697A IL124676A0 (en) 1996-01-25 1997-01-27 Improved concentrated injection and infusion solutions for intravenous use
BG102644A BG62913B1 (bg) 1996-01-25 1998-07-21 Подобрени концентрирани инжекционни и инфузионни разтвори за интравазално прилагане
NO983438A NO983438L (no) 1996-01-25 1998-07-24 Forbedrede konsentrerte injeksjons- og infusjonsl°sninger for intravasal anvendelse
US09/504,108 US6638913B1 (en) 1996-01-25 2000-02-14 Concentrated injection and infusion solution for intravenous administration

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19604095 1996-01-25
DE19604095.7 1996-01-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/504,108 Division US6638913B1 (en) 1996-01-25 2000-02-14 Concentrated injection and infusion solution for intravenous administration

Publications (2)

Publication Number Publication Date
WO1997026862A2 WO1997026862A2 (de) 1997-07-31
WO1997026862A3 true WO1997026862A3 (de) 1997-10-23

Family

ID=7784538

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1997/000170 Ceased WO1997026862A2 (de) 1996-01-25 1997-01-27 Verbesserte konzentrierte injektions- und infusionslösungen für die intravasale anwendung

Country Status (21)

Country Link
US (1) US6638913B1 (de)
EP (1) EP0876140B1 (de)
JP (1) JP2000505789A (de)
KR (1) KR100505772B1 (de)
CN (1) CN1209751A (de)
AT (1) ATE251893T1 (de)
AU (1) AU2150497A (de)
BG (1) BG62913B1 (de)
BR (1) BR9707081A (de)
CA (1) CA2244209C (de)
CZ (1) CZ234898A3 (de)
DE (2) DE59710863D1 (de)
DK (1) DK0876140T3 (de)
ES (1) ES2208884T3 (de)
HU (1) HUP9901355A3 (de)
IL (1) IL124676A0 (de)
NO (1) NO983438L (de)
PL (1) PL328199A1 (de)
PT (1) PT876140E (de)
SK (1) SK101398A3 (de)
WO (1) WO1997026862A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
CA2298475A1 (en) * 1997-10-31 1999-05-14 Walter Reed Army Institute Of Research Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules
DK1087934T3 (da) 1998-04-01 2004-06-28 Cardiome Pharma Corp Aminocyclohexyletherforbindelser og anvendelser deraf
US7057053B2 (en) 2000-10-06 2006-06-06 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US7524879B2 (en) 2000-10-06 2009-04-28 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
AU2002213441B2 (en) 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
US20020169112A1 (en) * 2001-05-08 2002-11-14 Luc Montagnier Combined treatments and methods for treatment of mycoplasma and mycoplasma-like organism infections
DE10244847A1 (de) * 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
CA2524323C (en) 2003-05-02 2012-05-15 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof
US7345087B2 (en) 2003-10-31 2008-03-18 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof
WO2005097087A2 (en) 2004-04-01 2005-10-20 Cardiome Pharma Corp. Merged ion channel modulating compounds and uses thereof
CA2561819A1 (en) 2004-04-01 2005-12-01 Cardiome Pharma Corp. Prodrugs of ion channel modulating compounds and uses thereof
US8263638B2 (en) 2004-11-08 2012-09-11 Cardiome Pharma Corp. Dosing regimens for ion channel modulating compounds
US20060270708A1 (en) * 2005-05-25 2006-11-30 Navinta Llc Novel process for preparation of isotonic aqueous injection of ropivacaine
EP1897535A1 (de) * 2006-08-30 2008-03-12 Dirinco AG Substitutionsflüssigkeit für die Haemofiltration
US20090239894A1 (en) * 2008-03-20 2009-09-24 Bjorn Schurad Stabilized aqueous solutions of ergoline compounds
AU2010221156A1 (en) 2009-03-06 2011-09-22 Genentech, Inc. Antibody formulation
US9427186B2 (en) * 2009-12-04 2016-08-30 Endomagnetics Ltd. Magnetic probe apparatus
US10634741B2 (en) 2009-12-04 2020-04-28 Endomagnetics Ltd. Magnetic probe apparatus
PT3345615T (pt) 2010-03-01 2020-01-17 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
CN102319258B (zh) * 2011-08-04 2012-10-31 山西诺成制药有限公司 一种5%葡萄糖置换液及其制备方法
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
ES2803506T3 (es) 2013-03-11 2021-01-27 Endomagnetics Ltd Soluciones hipoosmóticas para la detección de ganglios linfáticos
US9234877B2 (en) 2013-03-13 2016-01-12 Endomagnetics Ltd. Magnetic detector
US9239314B2 (en) 2013-03-13 2016-01-19 Endomagnetics Ltd. Magnetic detector
WO2014158965A1 (en) * 2013-03-27 2014-10-02 Ge Healthcare As Method and reagent for preparing a diagnostic composition
MX390935B (es) 2015-06-04 2025-03-21 Endomagnetics Ltd Materiales marcadores y formas para la localización de marcadores magnéticos (mml).
WO2019201904A1 (en) * 2018-04-16 2019-10-24 Merck Patent Gmbh Viscosity reduction of highly concentrated protein formulations
CN110327292A (zh) * 2019-08-11 2019-10-15 天津乾丰瑞科技有限公司 一种盐酸法舒地尔注射制剂及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2435253A1 (fr) * 1978-07-04 1980-04-04 Nyegaard & Co As Procede de preparation d'une solution tamponnee d'une substance de contraste pour rayons x, et produits obtenus par ce procede
EP0260811A2 (de) * 1986-08-21 1988-03-23 Vestar, Inc. Phospholipidpartikeln mit eingeschlossenen Polyen-Antibiotika zur Behandlung von systemischen Pilzinfektionen
WO1989009614A1 (en) * 1988-04-15 1989-10-19 Genentech, Inc. Human growth hormone formulation
EP0437622A1 (de) * 1989-07-07 1991-07-24 Kyowa Hakko Kogyo Co., Ltd. Beständige motilin-herstellung

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE754523A (fr) * 1969-08-06 1971-02-08 Beecham Group Ltd Vaccins
EP0077354A4 (de) * 1981-04-27 1983-09-30 Baxter Travenol Lab Dialyselösung glukose, aminosäuren und insulin enthaltend.
ATE82500T1 (de) * 1984-06-22 1992-12-15 Richard L Veech Elektrolytloesungen und deren (in vivo) verwendung.
GB8906130D0 (en) * 1989-03-17 1989-05-04 Nycomed As Compositions
ATE111585T1 (de) 1990-01-18 1994-09-15 Cereria Amos Sgarbi Spa Grablicht.
GB9020091D0 (en) * 1990-09-14 1990-10-24 Nycomed As Contrast media
DE4135193C1 (de) * 1991-10-22 1993-03-11 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De
IT1256248B (it) * 1992-12-24 1995-11-29 Bracco Spa Formulazioni iniettabili acquose per radiodiagnostica comprendenti miscele di composti aromatici iodurati utili come agenti opacizzanti ai raggi x
WO1995026331A1 (es) * 1994-03-25 1995-10-05 Centro Investigacion Justesa Imagen, S.A. Nuevos dimeros iodados no ionicos como agentes de contraste a los rayos x, metodo para su preparacion y composiciones farmaceuticas que los contienen
DE4446694A1 (de) * 1994-12-09 1996-06-13 Schering Ag Verwendung von Zusätzen zu Kontrastmitteln zur Verbesserung der Bildgebung

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2435253A1 (fr) * 1978-07-04 1980-04-04 Nyegaard & Co As Procede de preparation d'une solution tamponnee d'une substance de contraste pour rayons x, et produits obtenus par ce procede
EP0260811A2 (de) * 1986-08-21 1988-03-23 Vestar, Inc. Phospholipidpartikeln mit eingeschlossenen Polyen-Antibiotika zur Behandlung von systemischen Pilzinfektionen
WO1989009614A1 (en) * 1988-04-15 1989-10-19 Genentech, Inc. Human growth hormone formulation
EP0437622A1 (de) * 1989-07-07 1991-07-24 Kyowa Hakko Kogyo Co., Ltd. Beständige motilin-herstellung

Also Published As

Publication number Publication date
KR100505772B1 (ko) 2005-10-25
DE59710863D1 (de) 2003-11-20
US6638913B1 (en) 2003-10-28
HUP9901355A3 (en) 2000-06-28
CA2244209A1 (en) 1997-07-31
ES2208884T3 (es) 2004-06-16
JP2000505789A (ja) 2000-05-16
EP0876140A2 (de) 1998-11-11
CN1209751A (zh) 1999-03-03
ATE251893T1 (de) 2003-11-15
WO1997026862A2 (de) 1997-07-31
AU2150497A (en) 1997-08-20
BR9707081A (pt) 1999-05-25
DK0876140T3 (da) 2003-12-15
IL124676A0 (en) 1998-12-06
BG62913B1 (bg) 2000-11-30
PT876140E (pt) 2004-02-27
KR19990081979A (ko) 1999-11-15
NO983438L (no) 1998-09-18
CA2244209C (en) 2007-10-23
NO983438D0 (no) 1998-07-24
PL328199A1 (en) 1999-01-18
CZ234898A3 (cs) 1998-11-11
HUP9901355A2 (hu) 1999-08-30
DE19703816A1 (de) 1997-08-07
BG102644A (bg) 1999-06-30
SK101398A3 (en) 1998-12-02
EP0876140B1 (de) 2003-10-15

Similar Documents

Publication Publication Date Title
WO1997026862A3 (de) Verbesserte konzentrierte injektions- und infusionslösungen für die intravasale anwendung
ZA98361B (en) Hypodermic injection system.
AU3068599A (en) Medication infusion set
AU8923398A (en) Subcutaneous infusion set with dynamic needle
AU6135399A (en) Intravenous infusion needle with soft body
EP0648511A3 (de) Injektionsspritze.
ZA929225B (en) Injection syringe.
GB9401857D0 (en) Intravenous infusion set
ZA99104B (en) Method for administering ASPB28-human insulin.
EP0971758A4 (de) System zur intravenösen infusion
EP0590757A3 (de) Sichere Einwegspritze mit zurückziehender selbstvorgespannter Nadel.
AU8101794A (en) Medication injector
AU695171B2 (en) Enrofloxacine injection or infusion solutions
AU2377197A (en) Improved drug injection system with self-aspiration feature
ZA200101590B (en) Improved stability for injection solutions.
AU1404800A (en) Syringe and coordinated needle set for injections and more specifically for orthodental anesthesia
AU4481599A (en) Enema syringe, enema syringe auxiliary and injector and enema method using them
AU4972397A (en) I.v. catheter with needle guard
AU5737094A (en) Intravenous cannula assembly
AU1792401A (en) Injectors, injector systems and injector control
ZA200107275B (en) Hypodermic injection system.
AU6408400A (en) Tapered intravenous cannula
AU5563998A (en) Injection syringe with needle projecting in the syringe body
AU671693B2 (en) Intravenous infusion set
AU2003204565A1 (en) Improved concentrated injection and infusion solutions for intravascular use

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97191871.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU AZ BB BG BR BY CA CN CZ EE GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AU AZ BB BG BR BY CA CN CZ EE GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG KE

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1997914098

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PV1998-2348

Country of ref document: CZ

Ref document number: 1019980705697

Country of ref document: KR

Ref document number: 101398

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 2244209

Country of ref document: CA

Ref document number: 2244209

Country of ref document: CA

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: PV1998-2348

Country of ref document: CZ

Ref document number: 1997914098

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019980705697

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1997914098

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1019980705697

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV1998-2348

Country of ref document: CZ